Laudio Insights Releases “Leader Inspired Work” to Empower Healthcare’s Critical Frontline Leaders

Pii Introduces Accelevate™ Early Development Platform, Enabling IND Submissions in 100 Days for Aseptic Products

New Platform Reduces IND Submission Timelines for Small and Mid-Sized Pharma Companies.

Synexa Life Sciences Expands Bioanalysis Capabilities with the Acquisition of CRO Alderley Analytical

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, reflecting an important milestone in Synexa’s ‘buy and build’ growth strategy. By combining the two complementary companies, the group can now offer an even more comprehensive range of services to an enlarged customer base, both in large and small molecule drug development, and ranging from pre-clinical work to phase III clinical studies.

Phreesia and Ad Council Partnership Yields High Patient Engagement in 3 Mental Health Awareness Campaigns

Coronado Research announce engagement of Rob Nichols to support the growth of their Clinical Technology Practice

Coronado Research announced the engagement of Rob Nichols to support the build-out of its clinical technology practice and advise the executive leadership team as they deliver the broader company vision.

Certara Completes Acquisition of Chemaxon

The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.

CAI Appoints Sheena Dempsey as Chief Executive Officer

Proscia Launches Concentriq Embeddings and Developer Toolkit to Unleash Pathology AI Development

Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, today announced the launch of Concentriq® Embeddings and the Proscia AI Toolkit, enabling life sciences organizations to accelerate the discovery and development of novel therapies and diagnostics.

MATTER launches first Paratus Digital Health Hub Readiness Accelerator as part of BARDA Accelerator Network

The accelerator seeks next-generation digital health solutions supporting preparedness and response to health security threats

Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity

Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development

Sphere Fluidics has introduced Cyto-Mine Chroma – the second generation of its award-winning, flagship Cyto-Mine single cell analysis and isolation platform. With the upgrade to a four-color laser and detector system, Chroma offers enhanced capabilities to further maximise the efficiency and precision of single-cell functional analysis workflows. By accelerating the early selection of superior candidate cells, it supports project timelines to be reduced from months to weeks, and minimising effort and cost.

Zymo Research & BluMaiden Biosciences Announce Partnership to Provide Clinical Trial Analytics and Reporting Services to the Pharmaceutical Sector

This press release announces the partnership between Zymo Research and BluMaiden Biosciences to provide end-to-end clinical trial analytics and reporting services based on the human microbiome. We believe this development will be of significant interest to your audience, particularly those working in the pharmaceutical sector. The press release highlights how the new joint service will cover every stage of human microbiome analysis, including fit-for-purpose sample collection, nucleic acid purification, next-generation sequencing, sophisticated bioinformatics data analysis, and detailed clinical trial reporting. This service is designed to be applicable across entire trial cohorts and can be applied to a broad range of disease indications and intervention modalities, making it especially valuable for researchers and professionals in the pharma industry with the aim of enhancing therapeutic efficacy and commercial lifespan.

Vaxess Receives National Institutes of Health Grant to Explore Administering Type 2 Diabetes Treatment via the MIMIX™ Transdermal Patch Platform

The National Institute of Diabetes and Digestive and Kidney Diseases Awards Vaxess SBIR Phase I Funding to Test Company’s MIMIX Transdermal Patch Platform in Administering GLP-1 RA Therapies

Recipharm and Exela announce exclusive strategic alliance

VieCure Secures $45 Million Financing to Accelerate Adoption of First AI-Enabled Community Oncology Care Platform

VieCure Inc. announced the completion of a $45 million financing led by Northpond Ventures and the appointment of industry veteran Richard Daly as chairman of the board of directors.

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform

ResultsCX Named 'Major Contender' in Everest Group's Customer Experience Management Services PEAK Matrix® Assessment 2024, Americas

ResultsCX, a provider of Customer Experience Management (CXM) services to leading global companies including Fortune 100 and 500 firms, today announced it was honored as a Major Contender in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® Assessment (Americas region) for the fourth consecutive year. This recognition underlines the company’s ongoing expansion and commitment to supporting organizations across industries in optimizing consumer experience (CX) and driving growth.

Takara Bio Europe unveils new large-scale NGS profiling system and chemistries

Takara Bio Europe has announced the launch of the Shasta™ Single-Cell System, a high-throughput NGS solution enabling novel biomarker discovery in oncology research, at the 2024 Human Cell Atlas General Meeting. This comprehensive system combines well-validated chemistries with user-friendly bioinformatics tools, allowing researchers to mine more genomic and transcriptomic information from a much greater number of cells than previously possible, all while reducing both time and costs. The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit increases throughput by processing up to 1,500 cells per run, compared to current technologies which are limited to 384 single cells, while also enabling the detection of single-cell level CNV events via shallow sequencing. Its ability to detect RNA biotypes, such as non-polyadenylated lncRNAs, otherwise missed by current droplet-based technologies represents a significant advancement over traditional plate-based full-length RNA-seq and high-throughput mRNA-seq methods.

CRDSA Announces Publication of Standards for Clinical Trial Data Reuse

The Clinical Research Data Sharing Alliance (CRDSA), a multi-stakeholder consortium that serves the clinical research data ecosystem, has announced the publication of two new standards; the Standard for Sharing Clinical Study Data and the Standard for Secondary Analysis of Clinical Study Data. CRDSA developed these standards in response to common challenges faced by both data contributors and researchers. These new standards aim to facilitate the responsible sharing and use of anonymized individual patient data from clinical studies to support the research community and accelerate the discovery and delivery of new therapies to patients.

Cytiva and Pear Bio empower personalized cancer medicine with innovative single-cell technology